Reloadable multidrug capturing delivery system for targeted ischemic disease treatment

Area of Science:

• Biomedical Engineering
• Drug Delivery Systems
• Regenerative Medicine

Background:

• Protein therapies for ischemic diseases face challenges due to short drug half-life and poor site-specific retention.
• Polyethylene glycol (PEG)ylation improves protein drug circulation but hinders target site accumulation.
• Existing delivery methods limit the efficacy of complex, multi-stage protein therapies.

Purpose of the Study:

• To develop and evaluate a novel drug capture system for enhancing the retention of PEGylated protein therapeutics at target injury sites.
• To address the limitations of current protein therapies for ischemic conditions.
• To enable sequential administration of therapeutics for improved treatment outcomes.

Main Methods:

• Development of a drug capture system using a mixture of hyaluronic acid (HA) hydrogel and anti-PEG immunoglobulin M antibodies.
• In vivo testing of the HA/anti-PEG system in murine and porcine models of critical limb ischemia.
• Demonstration of the system's ability to capture and retain systemically injected PEGylated therapeutics.
• Validation of the 'reloading' capability for sequential drug administration.

Main Results:

• The HA/anti-PEG system successfully captured and retained PEGylated therapeutics at the target site in preclinical models.
• The system demonstrated efficacy in both murine and porcine models of critical limb ischemia.
• Repeated injections allowed for effective 'reloading' of the capture depot, supporting multistage therapies.
• The developed system showed potential for clinical application in treating ischemic diseases.

Conclusions:

• The reloadable HA/anti-PEG drug capture system offers a promising solution for improving protein therapy delivery in ischemic diseases.
• This innovative approach can overcome the limitations of poor drug retention and enable complex therapeutic regimens.
• The system holds significant potential for clinical translation to benefit patients with ischemic conditions requiring sequential protein drug administration.